


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of formula I:



wherein

X^1 , X^2 , X^3 , X^4 , and X^5 are independently selected from the group consisting of C, CR^5 , N, O, and S, wherein at least one of X^1 , X^2 , X^3 , X^4 , and X^5 is not N;

X^6 is selected from the group consisting of a bond and CR^5R^6 ;

X^7 is CR^5 or N;

X^8 is selected from the group consisting of a bond, CR^5R^6 , NR^5 , O, S, SO, and SO_2 ;

X^9 is CR^5 or N ;

X^{10} is selected from the group consisting of a bond, CR^5R^6 , $(CR^5R^6)_2$, O , S , and NR^5 ;

R^1 is selected from the group consisting of hydroxy, halo, nitro, C_{1-6} alkylhalo, OC_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, C_{2-6} alkenyl, OC_{2-6} alkenyl, C_{2-6} alkynyl, OC_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, OC_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl, OC_{0-6} alkylaryl, CHO , $(CO)R^5$, $O(CO)R^5$, $O(CO)OR^5$, $O(CN)OR^5$, C_{1-6} alkyl OR^5 , OC_{2-6} alkyl OR^5 , C_{1-6} alkyl $(CO)R^5$, OC_{1-6} alkyl $(CO)R^5$, C_{0-6} alkyl CO_2R^5 , OC_{1-6} alkyl CO_2R^5 , C_{0-6} alkylcyano, OC_{2-6} alkylcyano, C_{0-6} alkyl NR^5R^6 , OC_{2-6} alkyl NR^5R^6 , C_{1-6} alkyl $(CO)NR^5R^6$, OC_{1-6} alkyl $(CO)NR^5R^6$, C_{0-6} alkyl $NR^5(CO)R^6$, OC_{2-6} alkyl $NR^5(CO)R^6$, C_{0-6} alkyl $NR^5(CO)NR^5R^6$, C_{0-6} alkyl SR^5 , OC_{2-6} alkyl SR^5 , C_{0-6} alkyl $(SO)R^5$, OC_{2-6} alkyl $(SO)R^5$, C_{0-6} alkyl SO_2R^5 , OC_{2-6} alkyl SO_2R^5 , C_{0-6} alkyl $(SO_2)NR^5R^6$, OC_{2-6} alkyl $(SO_2)NR^5R^6$, C_{0-6} alkyl $NR^5(SO_2)R^6$, OC_{2-6} alkyl $NR^5(SO_2)R^6$, C_{0-6} alkyl $NR^5(SO_2)NR^5R^6$, OC_{2-6} alkyl $NR^5(SO_2)NR^5R^6$, $(CO)NR^5R^6$, $O(CO)NR^5R^6$, NR^5OR^6 , C_{0-6} alkyl $NR^5(CO)OR^6$, OC_{2-6} alkyl $NR^5(CO)OR^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R^2 is selected from the group consisting of hydrogen, hydroxy, halo, nitro, C_{1-6} alkylhalo, OC_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, C_{2-6} alkenyl, OC_{2-6} alkenyl, C_{2-6} alkynyl, OC_{2-6} alkynyl, C_{0-6} alkyl C_{3-6} cycloalkyl, OC_{0-6} alkyl C_{3-6} cycloalkyl, C_{0-6} alkylaryl, OC_{0-6} alkylaryl, CHO , $(CO)R^5$, $O(CO)R^5$,

$\text{O}(\text{CO})\text{OR}^5$, $\text{O}(\text{CN})\text{OR}^5$, $\text{C}_{1-6}\text{alkylOR}^5$, $\text{OC}_{2-6}\text{alkylOR}^5$, $\text{C}_{1-6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{OC}_{1-6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{C}_{0-6}\text{alkylCO}_2\text{R}^5$, $\text{OC}_{1-6}\text{alkylCO}_2\text{R}^5$, $\text{C}_{0-6}\text{alkylcyano}$, $\text{OC}_{2-6}\text{alkylcyano}$, $\text{C}_{0-6}\text{alkylNR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5\text{R}^6$, $\text{C}_{1-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$, $\text{OC}_{1-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{CO})\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylSR}^5$, $\text{OC}_{2-6}\text{alkylSR}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{C}_{0-6}\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2-6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $(\text{CO})\text{NR}^5\text{R}^6$, $\text{O}(\text{CO})\text{NR}^5\text{R}^6$, NR^5OR^6 , $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R^3 is a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R^4 is selected from the group consisting of hydroxy, halo, nitro, $\text{C}_{1-6}\text{alkylhalo}$, $\text{OC}_{1-6}\text{alkylhalo}$, $\text{C}_{1-6}\text{alkyl}$, $\text{OC}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{OC}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{OC}_{2-6}\text{alkynyl}$, $\text{C}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, $\text{OC}_{0-6}\text{alkylC}_{3-6}\text{cycloalkyl}$, $\text{C}_{0-6}\text{alkylaryl}$, $\text{OC}_{0-6}\text{alkylaryl}$, CHO , $(\text{CO})\text{R}^5$, $\text{O}(\text{CO})\text{R}^5$, $\text{O}(\text{CO})\text{OR}^5$,

$\text{O}(\text{CN})\text{OR}^5$, $\text{C}_{1-6}\text{alkylOR}^5$, $\text{OC}_{2-6}\text{alkylOR}^5$, $\text{C}_{1-6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{OC}_{1-6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{C}_{0-6}\text{alkylCO}_2\text{R}^5$, $\text{OC}_{1-6}\text{alkylCO}_2\text{R}^5$, $\text{C}_{0-6}\text{alkylcyano}$, $\text{OC}_{2-6}\text{alkylcyano}$, $\text{C}_{0-6}\text{alkylNR}^5\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5\text{R}^6$, $\text{C}_{1-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$, $\text{OC}_{1-6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{R}^6$, $\text{OC}_{2-6}\text{alkylNR}^5(\text{CO})\text{R}^6$, $\text{C}_{0-6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^6$, $\text{C}_{0-6}\text{alkylSR}^5$, $\text{OC}_{2-6}\text{alkylSR}^5$, $\text{C}_{0-6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2-6}\text{alkyl}(\text{SO})\text{R}^5$, C_{0-6}

$_6\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2,6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{OC}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^6$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $\text{OC}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^6$, $(\text{CO})\text{NR}^5\text{R}^6$, $\text{O}(\text{CO})\text{NR}^5\text{R}^6$, NR^5OR^6 , $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, $\text{OC}_{2,6}\text{alkylNR}^5(\text{CO})\text{OR}^6$, SO_3R^5 and a 5- or 6-membered ring containing atoms independently selected from the group consisting of C, N, O and S, wherein said ring may be substituted by one or more A;

R^5 and R^6 are independently selected from the group consisting of hydrogen, $\text{C}_{1,6}\text{alkyl}$, $\text{C}_{3,7}\text{cycloalkyl}$ and aryl;

A is selected from the group consisting of hydrogen, hydroxy, halo, nitro, $\text{C}_{1,6}\text{alkylhalo}$, $\text{OC}_{1,6}\text{alkylhalo}$, $\text{C}_{1,6}\text{alkyl}$, $\text{OC}_{1,6}\text{alkyl}$, $\text{C}_{2,6}\text{alkenyl}$, $\text{OC}_{2,6}\text{alkenyl}$, $\text{C}_{2,6}\text{alkynyl}$, $\text{OC}_{2,6}\text{alkynyl}$, $\text{C}_{0,6}\text{alkylC}_{3,6}\text{cycloalkyl}$, $\text{OC}_{0,6}\text{alkylC}_{3,6}\text{cycloalkyl}$, $\text{C}_{0,6}\text{alkylaryl}$, $\text{OC}_{0,6}\text{alkylaryl}$, CHO , $(\text{CO})\text{R}^5$, $\text{O}(\text{CO})\text{R}^5$, $\text{O}(\text{CO})\text{OR}^5$, $\Theta(\text{CN})\text{OR}^5$, $\text{C}_{1,6}\text{alkylOR}^5$, $\text{OC}_{2,6}\text{alkylOR}^5$, $\text{C}_{1,6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{OC}_{1,6}\text{alkyl}(\text{CO})\text{R}^5$, $\text{C}_{0,6}\text{alkylCO}_2\text{R}^5$, $\text{OC}_{1,6}\text{alkylCO}_2\text{R}^5$, $\text{C}_{0,6}\text{alkylcyano}$, $\text{OC}_{2,6}\text{alkylcyano}$, $\text{C}_{0,6}\text{alkylNR}^5\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5\text{R}^8$, $\text{C}_{1,6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^8$, $\Theta\text{C}_{1,6}\text{alkyl}(\text{CO})\text{NR}^5\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{CO})\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{CO})\text{NR}^5\text{R}^8$, $\text{C}_{0,6}\text{alkylSR}^5$, $\text{OC}_{2,6}\text{alkylSR}^5$, $\text{C}_{0,6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{OC}_{2,6}\text{alkyl}(\text{SO})\text{R}^5$, $\text{C}_{0,6}\text{alkylSO}_2\text{R}^5$, $\text{OC}_{2,6}\text{alkylSO}_2\text{R}^5$, $\text{C}_{0,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkyl}(\text{SO}_2)\text{NR}^5\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{R}^8$, $\text{C}_{0,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{SO}_2)\text{NR}^5\text{R}^8$, $(\text{CO})\text{NR}^5\text{R}^8$, $\text{O}(\text{CO})\text{NR}^5\text{R}^8$, NR^5OR^8 , $\text{C}_{0,6}\text{alkylNR}^5(\text{CO})\text{OR}^8$, $\Theta\text{C}_{2,6}\text{alkylNR}^5(\text{CO})\text{OR}^8$, SO_3R^5 and a 5- or 6-

membered ring containing atoms independently selected from the group consisting of C, N, O and S;

n is 0, 1, 2, 3, or 4; or

a pharmaceutically acceptable salt or hydrate thereof;

provided that:

a) when $X_2-X^2 = X_4-X^4 = X_5-X^5 = N$, and either of X_8-X^8 or $X_{10}-X^{10}$ is a bond, then X_9-X^9 is not N,

b) when X^7 is N at least two of X^1, X^2, X^3, X^4 , and X^5 are not N,

c) X^1 and X^3 are not O;

and provided that the compound is not:

8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine,

8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-thiophen-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine,

8-[5-(5-Chloro-2-fluoro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine;

8-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[5-(5-Chloro-2-fluoro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[5-(3-Chloro-phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[1-[5-(3-Chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-ethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[5-(5-Chloro-2-fluoro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-furan-2-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

8-[1-[5-(3-Chloro-phenyl)-[1,2,4]oxadiazol-3-yl]-ethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

3-Pyridine-4-yl-8-[1-(5-m-tolyl)-[1,2,4]oxadiazol-3-yl]-ethyl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

(+)-8-[(1S)-1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

(-)-8-[(1R)-1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-3-pyridine-4-yl-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrimidine;

3-{5-[3-(Pyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl)][1,3,4]oxadiazol-2-yl}benzonitrile;

3-{5-[3-(2-Methoxypyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl)][1,3,4]oxadiazol-2-yl}benzonitrile;

3-{5-[3-(2-Methoxy-pyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,2,4]oxadiazol-3-yl}benzonitrile;

3-{3-[(3-pyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-5-yl}benzonitrile;


3-(3-[[3-(2-methoxypyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-5-yl]benzonitrile;

3-{5-[(3-pyridin-4-yl)-6,7-dihydro[1,2,4]triazolo[4,3-a]pyrimidin-8(5H)-yl)methyl]-1,2,4-oxadiazol-3-yl}benzonitrile; and

3-{5-[3-(2-Hydroxy-pyridin-4-yl)-6,7-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-8-ylmethyl]-[1,2,4]oxadiazol-3-yl}benzonitrile.


2. (Withdrawn) The compound according to claim 1, provided that the compound is not 8-[5-(5-Chloro-phenyl)-[1,2,4]oxadiazol-3-ylmethyl]-3-furan-2-yl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine,

3. **(Original)** The compound according to claim 1, wherein R^1 is halo, C_{1-6} alkylhalo, C_{1-6} alkyl, OC_{1-6} alkyl, or C_{0-6} alkylcyano.
4. **(Original)** The compound according to claim 1, wherein R^2 is hydrogen or halo.
5. **(Original)** The compound according to claim 1, wherein R^2 is fluorine.
6. **(Original)** The compound according to claim 1, of Formula II:



7. **(Original)** The compound according to claim 6, wherein X^7 is N.


8. **(Currently Amended)** The compound according to ~~claim 0~~claim 1, of Formula III:




9. **(Original)** The compound according to claim 8, wherein X^3 is C.

10. **(Original)** The compound according to claim 8, wherein X^3 is N.

11. **(Currently Amended)** The compound according to ~~claim 0~~claim 1, wherein the ring containing X^1 , X^2 , X^3 , X^4 , and X^5 is selected from the group consisting of:




12. **(Original)** The compound according to claim 11, wherein the ring is selected from the group consisting of:



13. **(Original)** The compound according to claim 11, wherein X^7 is N.
14. **(Withdrawn)** The compound according to claim 13, wherein X^8 is a bond.
15. **(Original)** The compound according to claim 13, wherein X^8 is S.
16. **(Withdrawn)** The compound according to claim 14, wherein X^9 is CR^5 .
17. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is NR^5 .
18. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is O.

19. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is CR^5R^6 .
20. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is $(CR^5R^6)_2$.
21. **(Withdrawn)** The compound according to claim 16, wherein X^{10} is a bond.
22. **(Original)** The compound according to claim 15, wherein X^9 is CR^5 .
23. **(Original)** The compound according to claim 22, wherein X^{10} is a bond.
24. **(Withdrawn)** The compound according to claim 14, wherein X^9 is N.
25. **(Currently Amended)** The compound according to claim 11, wherein the fused ring containing X^7 , X^8 , X^9 , and X^{10} is selected from the group consisting of:



26. **(Currently Amended)** The compound according to claim 1 selected from the group consisting of: which is

7-[5-(5-Chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-3-(2-thienyl)-6,7-dihydro-5H-[1,2,4]triazolo[3,4-b][1,3]thiazine,

9-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

9-[1-[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]ethyl]-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

7-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-pyridin-4-yl-6,7-dihydro-5H-pyrrolo[2,1-e][1,2,4]triazole,

9-[[5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]-3-(trifluoromethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

8-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-3-(4-methoxy-phenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine,

8-[3-(3-Chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-3-(4-methoxy-phenyl)-7-methyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine,

9-[[5-(3-chlorophenyl)isoxazol-3-yl]methyl]-3-(3,5-difluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine,

~~9-([5-(3-chlorophenyl)isoxazol-3-yl]methyl)-3-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;~~
~~9-([5-(3-chlorophenyl)isoxazol-3-yl]methyl)-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;~~
~~9-([5-(5-chloro-2-fluorophenyl)-1,2,4-oxadiazol-3-yl]methyl)-3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;~~
~~9-([5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl)-3-(3,5-difluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine;~~
~~9-([5-(3-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl)-3-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a][1,3]diazepine; and~~

pharmaceutically acceptable salts thereof.

27. **(Currently Amended)** A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of the compound according to any one of claims 1, 3-13, 15, 22, 23, 25 and 26, and one or more pharmaceutically acceptable diluents, excipients, and/or inert carriers.

28. **(Canceled)**

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Currently Amended) The method according to any one of claims 32, 35, 36 and 37, wherein the mammal is a human.

34. (Canceled)

35. (Currently Amended) ~~The~~ A method for the treatment of ~~according to claim 32,~~
~~wherein the disorder is a psychiatric disorder~~ comprising administering to a mammal in need
thereof a therapeutically effective amount of the compound according to claim 1.

36. (Currently Amended) ~~The~~ A method for the treatment of ~~according to claim 32,~~
~~wherein the disorders are selected from chronic and acute pain disorders~~ comprising

administering to a mammal in need thereof a therapeutically effective amount of the compound according to claim 1.

37. **(Currently Amended)** ~~The A method for the treatment of gastro-esophageal reflux disorder (GERD) comprising administering to a mammal in need thereof a therapeutically effective amount of the compound according to claim 1~~according to claim 32, wherein the disorder is a gastrointestinal disorder.

38. **(Canceled)**